Advanced Viral Research said that, although preliminary, this study, which was conducted using pigs, provides the rationale for advancing AVR 118 to the human testing stage.
“This study has already generated interest from two major dermatological and wound healing centers in North America and Europe and we intend to move forward with a clinical trial plan,” commented Stephen Elliston, president and CEO of Advanced Viral Research.
“These findings are extremely important because the regenerative properties of the pig model closely parallel those of humans,” he continued.
AVR 118, the company’s lead product candidate, represents a new class of complex cytoprotective agents that target, among other things, cachexia-related disorders. Various degenerative conditions associated with cachexia such as cancer, HIV-AIDS and chronic inflammation are potential disease targets for AVR118 therapy.